Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Am Fam Physician ; 108(1): 28-39, 2023 07.
Artículo en Inglés | MEDLINE | ID: mdl-37440735

RESUMEN

Menopausal symptoms are widespread and significantly impact quality of life. Common symptoms of menopause are vasomotor (i.e., hot flashes and night sweats) and genitourinary (e.g., vulvovaginal irritation and dryness, dyspareunia, urinary problems), although women may also experience changes in sexual function, mood, and sleep. Estrogen-containing hormone therapy is effective treatment for vasomotor symptoms. Nonhormonal medications for vasomotor symptoms include selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and gabapentin. Selective serotonin reuptake inhibitors should not be administered to women taking tamoxifen. Cognitive behavior therapy and clinical hypnosis are effective for short-term reduction of vasomotor symptoms and associated sleep disturbances, but data are lacking to support the effectiveness of other nonpharmacologic treatments such as herbal or botanicalsupplements, exercise, and acupuncture. Hormone-free vaginal moisturizers are noninferior to estrogen-based therapies for treating genitourinary syndrome of menopause. Other treatment options for vaginal dryness and dyspareunia associated with menopause include ospemifene and intravaginal dehydroepiandrosterone. Management of menopausal symptoms should involve shared decision-making that is informed by the best available evidence and individual risks and preferences.


Asunto(s)
Dispareunia , Inhibidores Selectivos de la Recaptación de Serotonina , Femenino , Humanos , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Dispareunia/terapia , Dispareunia/tratamiento farmacológico , Calidad de Vida , Menopausia , Sofocos/tratamiento farmacológico , Estrógenos/uso terapéutico
2.
Am Fam Physician ; 107(2): 152-158, 2023 02.
Artículo en Inglés | MEDLINE | ID: mdl-36791447

RESUMEN

Skin conditions during pregnancy fall into three categories: benign hormone-related changes, preexisting skin conditions, and pregnancy-specific disorders. Benign hormonal skin changes (e.g., hyperpigmentation, striae gravidarum, hair and nail changes, vascular changes) are common during pregnancy and often improve or resolve postpartum. Topical therapies, including tretinoin, hydroquinone, and corticosteroids, can be helpful in the postpartum treatment of melasma. The severity of preexisting skin conditions such as acne vulgaris, condylomata acuminata, herpes simplex, hidradenitis suppurativa, and psoriasis varies during pregnancy. Treatment options for chronic skin conditions during pregnancy often differ from usual practice because of safety concerns. Discussion of potential risks and benefits is important. Low- to midpotency topical corticosteroids are generally considered safe during pregnancy, whereas extensive use of high-potency corticosteroids may be associated with low birth weight. Pregnancy-specific skin conditions include atopic eruption of pregnancy, polymorphic eruption of pregnancy, pemphigoid gestationis, intrahepatic cholestasis of pregnancy, and pustular psoriasis of pregnancy. Conditions that may cause adverse fetal outcomes and require consideration of antenatal fetal surveillance include intrahepatic cholestasis of pregnancy, pemphigoid gestationis, and pustular psoriasis of pregnancy.


Asunto(s)
Exantema , Penfigoide Gestacional , Complicaciones del Embarazo , Psoriasis , Enfermedades Cutáneas Vesiculoampollosas , Femenino , Embarazo , Humanos , Complicaciones del Embarazo/diagnóstico , Complicaciones del Embarazo/tratamiento farmacológico , Piel , Psoriasis/diagnóstico , Psoriasis/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...